Sector consensus Perspective Therapeutics, Inc.

Stocks

Real-time Estimate Cboe BZX Other stock markets 10:21:10 2026-08-11 am EDT			5-day change	1st Jan Change
3.165 ^USD	+5.50%		+4.17%	+13.64%

Aug. 10	Perspective Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Jul. 28	Perspective Therapeutics' Neuroendocrine Tumor Therapy Receives EU Orphan Drug Designation	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Average Target P.	Objective/dr gap	Nbr of analysts
PERSPECTIVE THERAPEUTICS, INC.	12.79	+326.19%	14
LONZA GROUP AG	681.13	+17.52%	23
REVOLUTION MEDICINES, INC.	220.81	+6.69%	21
BEONE MEDICINES AG	432.9	+20.58%	25
IQVIA HOLDINGS INC.	275.17	+13.71%	18
CELLTRION, INC.	264,708.89	+31.7%	24
ASCENDIS PHARMA A/S	267.31	+20.9%	18
MEDPACE HOLDINGS, INC.	581.83	-3.42%	12
EUROFINS SCIENTIFIC SE	72.53	+3.55%	14
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	281	+1.44%	14
ICON PUBLIC LIMITED COMPANY	185.56	+11.75%	16
PHARMARON BEIJING CO., LTD.	37.73	-19.77%	11
BIO-TECHNE CORPORATION	69.73	-3.32%	11
ABIVAX	138.56	+24.72%	6
PRAXIS PRECISION MEDICINES, INC.	623.68	+69.96%	19
APOGEE THERAPEUTICS, INC.	130.53	-3.06%	12
TEMPUS AI, INC.	62.64	+13.77%	14
PROTAGONIST THERAPEUTICS, INC.	165.31	+10.21%	13
IONIS PHARMACEUTICALS, INC.	89.33	+56.89%	21
QIAGEN N.V.	46.07	+5.06%	14
Average	13,454.18	+30.25%	16
Weighted average by Cap.	23,296.76	+15.32%	19